At the 6th China International Import Expo (CIIE) in Shanghai, Japan-based Takeda has inked a partnership with China-based New Horizon Health Technology Co., Ltd (HKG: 6606), a leading cancer diagnostics developer. The collaboration aims to develop a comprehensive management solution for Helicobacter pylori patients in China, underscoring Takeda’s (TYO: 4502) commitment to addressing critical health needs in the region.
Helicobacter pylori Management Solution
The partnership with New Horizon Health Technology focuses on creating a full course management solution for patients affected by Helicobacter pylori, a bacterium that can cause ulcers and is associated with an increased risk of gastric cancer. While financial details of the agreement were not disclosed, the collaboration signifies the potential for significant advancements in diagnostics and treatment for this common infection in China.
Deepening Collaboration with China Alliance for Rare Diseases (CARD)
In a separate announcement, Takeda revealed the deepening of its collaboration with the China Alliance for Rare Diseases (CARD), following their initial partnership in 2019. This expanded collaboration will utilize CARD’s resource platforms and Takeda’s expertise in rare diseases to enhance the construction of diagnosis and treatment capabilities for rare diseases in China.
Joint Efforts in Rare Disease Management
Together, Takeda and CARD will delve into various aspects of rare disease management, including the exploration of industrial development, disease management pathways, academic cooperation, and policy research. This collaboration aims to strengthen the ecosystem for rare disease diagnosis and treatment in China, providing much-needed support to patients and healthcare providers.-Fineline Info & Tech
